The results of two animal studies show that the drug ABthrax improves survival rates in by up to 64 percent when administered after animals were symptomatic for anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores, according to Human Genome Sciences, Inc. [HGSI], the developer of ABthrax. HGS says the results demonstrated a survival benefit in two animal species, which meets the requirement for establishing efficacy of new drugs used to counter bio-terrorism. "These…
Recommended
Hegseth Announces Plans For New Autonomous Warfare Command, Project Meridian Panel
Trending
Congress Updates
Rep. Himes Signals Increased Contractor Oversight, if Democrats Win House
Rep. Jim Himes (D-Conn.), the ranking member of the House Permanent Select Committee on Intelligence, plans to increase the committee’s contractor oversight if the Democrats win control of the House […]
CBO Estimates Loss of One-Half to Two-Thirds of U.S. Missile Interceptors Since June Last Year
A new Congressional Budget Office report estimates the cost of the Iran war through Aug. 1 as $38 billion and says that the U.S. has likely depleted between one-half and […]
Fischer Says Golden Dome Boosters Need To Increase Capitol Hill Support With Information, Warns Against Counting On Reconciliation
NATIONAL HARBOR, Md. – A Senate Armed Services panel chair today said boosters of the Golden Dome program still have work to do to increase support on Capitol Hill while […]
HII Executive Outlines Its Shipbuilding Acceleration Strategy
An HII [HII] shipbuilding executive last week told lawmakers how the company plans to improve and accelerate shipbuilding throughout via workforce improvements, adding new shipbuilding infrastructure and reinforcing distributed shipbuilding […]